Although researchers have revealed that directly blocking the expression of Tim-3 and PD-1 can restore the antitumor function of TILs in HBV-HCC [68], there are almost no relevant experimental data showing that targeted blockade of Tim-3 can inhibit the growth of HCC and improve the survival rate of patients. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.